Literature DB >> 7860736

Polyol profiles in Down syndrome. myo-Inositol, specifically, is elevated in the cerebrospinal fluid.

H U Shetty1, M B Schapiro, H W Holloway, S I Rapoport.   

Abstract

Polyols are reduction products of aldoses and ketoses; their concentrations in tissues can reflect carbohydrate metabolism. Several polyol species were quantitated in cerebrospinal fluid (CSF) and plasma from 10 Down Syndrome (trisomy 21) subjects between the ages of 22 and 63 years (3 of whom were demented) and from 10 healthy age-matched controls, using a gas chromatographic/mass spectrometric technique. The mean CSF concentration and the mean CSF/plasma concentration ratio of myo-inositol were significantly elevated in Down syndrome compared with controls, but were not correlated with the presence of dementia in the Down subjects. Plasma myo-inositol was not significantly altered in these subjects. No significant difference between Down syndrome and controls was found for CSF concentrations of mannitol, sorbitol, galactitol, ribitol, arabitol, or 1,5-anhydrosorbitol, but plasma mannitol, ribitol and arabitol were elevated in Down syndrome. The present observation provides new impetus for studying synthesis and transport of myo-inositol as well as phosphatidylinositol cycle in trisomy 21 disorder.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7860736      PMCID: PMC295508          DOI: 10.1172/JCI117696

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  26 in total

1.  Regional cerebral glucose metabolism is normal in young adults with Down syndrome.

Authors:  M B Schapiro; C L Grady; A Kumar; P Herscovitch; J V Haxby; A M Moore; B White; R P Friedland; S I Rapoport
Journal:  J Cereb Blood Flow Metab       Date:  1990-03       Impact factor: 6.200

Review 2.  Neural and developmental actions of lithium: a unifying hypothesis.

Authors:  M J Berridge; C P Downes; M R Hanley
Journal:  Cell       Date:  1989-11-03       Impact factor: 41.582

Review 3.  Metabolism and function of myo-inositol and inositol phospholipids.

Authors:  B J Holub
Journal:  Annu Rev Nutr       Date:  1986       Impact factor: 11.848

4.  Decline in cerebral glucose utilisation and cognitive function with aging in Down's syndrome.

Authors:  M B Schapiro; J V Haxby; C L Grady; R Duara; N L Schlageter; B White; A Moore; M Sundaram; S M Larson; S I Rapoport
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-06       Impact factor: 10.154

5.  Report of the Committee on the Genetic Constitution of Chromosomes 20, 21, and 22.

Authors:  P Tippett; J C Kaplan
Journal:  Cytogenet Cell Genet       Date:  1985

6.  Cerebral glucose utilization, as measured with positron emission tomography in 21 resting healthy men between the ages of 21 and 83 years.

Authors:  R Duara; R A Margolin; E A Robertson-Tchabo; E D London; M Schwartz; J W Renfrew; B J Koziarz; M Sundaram; C Grady; A M Moore
Journal:  Brain       Date:  1983-09       Impact factor: 13.501

7.  Lumbar cerebrospinal fluid choline in healthy aging and in Down's syndrome.

Authors:  M B Schapiro; J R Atack; I Hanin; C May; J V Haxby; S I Rapoport
Journal:  Arch Neurol       Date:  1990-09

8.  Myo-inositol transport through the blood-brain barrier.

Authors:  R Spector
Journal:  Neurochem Res       Date:  1988-08       Impact factor: 3.996

9.  Myo-inositol turnover in the intact rat brain: increased production after d-amphetamine.

Authors:  A I Barkai
Journal:  J Neurochem       Date:  1981-04       Impact factor: 5.372

10.  Neuropsychological evaluation of adults with Down's syndrome: patterns of selective impairment in non-demented old adults.

Authors:  J V Haxby
Journal:  J Ment Defic Res       Date:  1989-06
View more
  15 in total

1.  Measuring brain uptake and incorporation into brain phosphatidylinositol of plasma myo-[2H6]inositol in unanesthetized rats: an approach to estimate in vivo brain phosphatidylinositol turnover.

Authors:  Kaizong Ma; Joseph Deutsch; Nelly E Villacreses; Thad A Rosenberger; Stanley I Rapoport; H Umesha Shetty
Journal:  Neurochem Res       Date:  2006-06-22       Impact factor: 3.996

2.  Ts65Dn mouse, a Down syndrome model, exhibits elevated myo-inositol in selected brain regions and peripheral tissues.

Authors:  H U Shetty; R J Siarey; Z Galdzicki; J Stoll; S I Rapoport
Journal:  Neurochem Res       Date:  2000-04       Impact factor: 3.996

Review 3.  Peroxisomes of the Brain: Distribution, Functions, and Associated Diseases.

Authors:  Rachayeeta Deb; Neha Joshi; Shirisha Nagotu
Journal:  Neurotox Res       Date:  2021-01-05       Impact factor: 3.911

4.  Betaine in the Brain: Characterization of Betaine Uptake, its Influence on Other Osmolytes and its Potential Role in Neuroprotection from Osmotic Stress.

Authors:  Leena S Knight; Quinn Piibe; Ian Lambie; Christopher Perkins; Paul H Yancey
Journal:  Neurochem Res       Date:  2017-09-16       Impact factor: 3.996

5.  Identification of a mammalian H(+)-myo-inositol symporter expressed predominantly in the brain.

Authors:  M Uldry; M Ibberson; J D Horisberger; J Y Chatton; B M Riederer; B Thorens
Journal:  EMBO J       Date:  2001-08-15       Impact factor: 11.598

6.  CSF inositol does not predict antidepressant response to inositol. Short communication.

Authors:  J Levine; L Kurtzman; A Rapoport; J Zimmerman; Y Bersudsky; J Shapiro; R H Belmaker; G Agam
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

7.  myo-Inositol is an osmolyte in rat liver macrophages (Kupffer cells) but not in RAW 264.7 mouse macrophages.

Authors:  U Warskulat; C Weik; D Häussinger
Journal:  Biochem J       Date:  1997-08-15       Impact factor: 3.857

8.  Cerebrospinal fluid evidence of increased extra-mitochondrial glucose metabolism implicates mitochondrial dysfunction in multiple sclerosis disease progression.

Authors:  William T Regenold; Pornima Phatak; Michael J Makley; Roger D Stone; Mitchel A Kling
Journal:  J Neurol Sci       Date:  2008-09-09       Impact factor: 3.181

9.  Brain accumulation of myo-inositol in the trisomy 16 mouse, an animal model of Down's syndrome.

Authors:  H U Shetty; H W Holloway; L D Acevedo; Z Galdzicki
Journal:  Biochem J       Date:  1996-01-01       Impact factor: 3.857

10.  Relationship of cerebrospinal fluid glucose metabolites to MRI deep white matter hyperintensities and treatment resistance in bipolar disorder patients.

Authors:  William T Regenold; K Calvin Hisley; Pornima Phatak; Christopher M Marano; Abraham Obuchowski; David M Lefkowitz; Amritpal Sassan; Sameer Ohri; Tony L Phillips; Narveen Dosanjh; Robert R Conley; Rao Gullapalli
Journal:  Bipolar Disord       Date:  2008-11       Impact factor: 6.744

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.